• 1
    Wiggers P, Dalhoj I, Kiaer H, et al. Screening for haemochromatosis: prevalence among Danish blood donors. J Intern Med 1991; 230: 26570.
  • 2
    Elliott R, Lin BP, Dent OF, et al. Prevalence of haemochromatosis in a random sample of asymptomatic men. Aust NZ J Med 1986; 16: 4915.
  • 3
    Velanti C, Piperno A, Fargion S, et al. Prevalence of idiopathic haemochromatosis in Italy: study of 1301 blood donors. Haematologica 1990; 75: 30912.
  • 4
    Martinez-Vazquez C, Martinez Cadilla J, Gil M, et al. Prevalence of hereditary haemochromatosis among healthy workers. Diagnostic value of transferring saturation assay. Ann Intern Med 2000; 17: 628831.
  • 5
    Olsson KS, Ritter B, Rosen U, et al. Prevalence of iron overload in central Sweden. Acta Med Scand 1983; 213: 14550.
  • 6
    Asberg A, Hveem K, Thorstensen K, et al. Screening for haemochromatosis. high prevalence and low morbidity in an unselected population of 65,238 persons. Scan J Gastroenterol 2001; 36: 110815.
  • 7
    Ryan E, O'Keane C, Crowe J. Haemochromatosis in Ireland and HFE. Blood Cells Mol Dis 1998; 24: 42832.
  • 8
    Niederau C, Strohmeyer G, Stremmel W. Epidemiology, clinical spectrum and prognosis of haemochromatosis. Adr Exp Med Biol 1994; 356: 293302.
  • 9
    Karlsson M, Ikkala E, Reunanen A, et al. Prevalence of haemochromatosis in Finland. Acta Med Scand 1988; 224: 38590.
  • 10
    Miedzybrodzka Z, Loughlin S, Baty D, et al. Haemochromatosis mutations in North-East Scotland. Br J Haematol 1999; 106: 3857.
  • 11
    Distante S, Berg JP, Landek, et al. High prevalence of the haemochromatosis-associated Cyst282T HFE gene mutation in a healthy Norwegian population in the city of Oslo, and its phenotypic expression. Scand J Gastroenterol 1999; 34: 52934.
  • 12
    Larsen LE, Ellervik C, Appleyard M, et al. Prevalence of haemochromatosis-associated mutations in the haemochromatosis gene in the Danish population. Ugeskr Laeger 2002; 164: 45457.
  • 13
    Jouanolle AM, Fergelot P, Raoul ML, et al. Prevalence of the C282Y mutation in Brittany: penetrance of genetic haemochromatosis? Ann Genet 1998; 41: 1958.
  • 14
    Nielsen P, Carpinteiro S, Fischer R, et al. Prevalence of the C282Y and H63D mutations in the HFE gene in patients with hereditary haemochromatosis and in control subjects from Northern Germany. Br J Haematol 1998; 103: 8425.
  • 15
    Moczulski DR, Grezeszezak W, Gawlik B. Frequency of the haemochromatosis C282Y and H63D mutations in a Polish population of Slavic origin. Med Sci Monit 2001; 7: 4413.
  • 16
    Byrnes V, Ryan E, Barrett S, et al. Genetic haemochromatosis, a Celtic disease: is it now time for population screening? Genet Test 2001; 5: 12730.
  • 17
    Parlist P, Mikelsaar AV, Tasa G, Beckman L. The frequency of C282Y and H63D mutations in haemochromatosis gene in native Estonians. Eur J Epidemiol 2001; 17: 21316.
  • 18
    Sanchez M, Bruguera M, Quintero E, et al. Hereditary haemochromatosis in Spain. Gene Test 2000; 4: 1716.
  • 19
    Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, et al. Geography of HFE C282Y and H63D mutations. Gene Test 2000; 4: 18398.
  • 20
    Newsome PN, Bathgate AJ, Henderson NC, et al. Referral patterns and social deprevation in paracetamol-induced liver injury in Scotland. Lancet 2001; 358: 161213.
  • 21
    Schiodt FV, Shakil O, et al. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg 1999; 5: 2934.
  • 22
    Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 94754.
  • 23
    Orlewska E. The cost-effectiveness of alternative therapeutic strategies for the management of chronic hepatitis B in Poland. Value Health 2002; 5: 40420.
  • 24
    Cristani A, Cioni G, Vignoli A, et al. Early diagnosis of hepatocarcinoma: criteria for the performance of screening in patients with liver cirrhosis. Recenti Prog Med 1991; 82: 3946.
  • 25
    Younossi ZM, Boparai N, McCormick M, et al. Assessment of utilities and health related quality of life in patients with chronic liver disease. Am J Gastroenterol 2001; 96: 57983.
    Direct Link:
  • 26
    Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36: 5304.
  • 27
    Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997; 15: 86674.
  • 28
    Skeie B, Mirshra V, Vaaler S, Amilie E. A comparison of actual cost, DRG-based cost and hospital reimbursement of liver transplant patients. Transpl Int 2002; 15: 43945.
  • 29
    Taylor MC, Creig PD, Detsky AS, et al. Factors associated with the high cost of liver transplantation adults. Can J Surg 2002; 45: 42534.
  • 30
    Rosina F, Alaria P, Castelli S, et al. Effect of patient characteristics on hospital costs for cirrhosis, implications for the disease-related group (DRG) reimbursement system. Ital J Gastroenterol 1996; 28: 4015.